Stock Analysis

High Growth Tech Stocks In Asia With Promising Potential

The Asian tech market is experiencing notable growth, with indices such as the Nasdaq Composite reaching new highs and Chinese exports showing resilience despite global trade tensions. In this dynamic environment, identifying promising tech stocks involves looking for companies that demonstrate strong innovation capabilities and adaptability to shifting economic conditions.

Advertisement

Top 10 High Growth Tech Companies In Asia

NameRevenue GrowthEarnings GrowthGrowth Rating
Accton Technology22.79%22.79%★★★★★★
Shanghai Huace Navigation Technology25.19%23.94%★★★★★★
Zhejiang Lante Optics21.61%23.73%★★★★★★
PharmaEssentia31.60%57.71%★★★★★★
Fositek31.69%39.80%★★★★★★
Eoptolink Technology32.53%32.58%★★★★★★
Gold Circuit Electronics26.51%32.23%★★★★★★
eWeLLLtd24.95%24.40%★★★★★★
Shengyi Electronics26.23%37.08%★★★★★★
CARsgen Therapeutics Holdings81.53%96.08%★★★★★★

Click here to see the full list of 174 stocks from our Asian High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Essex Bio-Technology (SEHK:1061)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Essex Bio-Technology Limited is an investment holding company that develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally with a market capitalization of approximately HK$3.16 billion.

Operations: Essex Bio-Technology generates revenue primarily from its surgical and ophthalmology segments, with HK$879.90 million and HK$771.49 million respectively. The company also provides services contributing HK$18.42 million to its revenue stream.

Essex Bio-Technology has demonstrated a robust trajectory in the biotech sector, with its revenue and earnings growth outpacing the broader Hong Kong market. The company's annual revenue is expected to increase by 10.2%, surpassing the market's 8.1% growth rate, while its earnings are forecasted to climb at an impressive rate of 12% annually, compared to the market's 10.8%. Despite not outperforming the biotech industry’s average last year, Essex maintains a promising outlook with a projected Return on Equity of 22.5%. Additionally, recent corporate developments include a dividend increase and amendments to its bylaws which could enhance governance structures and shareholder returns moving forward.

SEHK:1061 Revenue and Expenses Breakdown as at Aug 2025
SEHK:1061 Revenue and Expenses Breakdown as at Aug 2025

WuXi Xinje ElectricLtd (SHSE:603416)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: WuXi Xinje Electric Co., Ltd. focuses on developing, producing, and selling industrial automation products both in China and internationally, with a market cap of CN¥8.81 billion.

Operations: The company generates revenue primarily from the instrument industry, with reported sales of CN¥1.76 billion.

WuXi Xinje Electric has carved a niche in the high-growth tech sector in Asia, demonstrating robust financial health with earnings growth of 22.8% annually and revenue surging by 20.3% each year, outpacing the broader Chinese market's growth of 12.6%. Despite a forecasted Return on Equity of 12.9%, which lags behind some industry benchmarks, the company's strategic focus on innovation is evident from its significant R&D investment, aligning with its impressive earnings trajectory. Recent developments from their Q1 2025 Earnings Call highlight continued expansion efforts and operational enhancements that could bolster future performance in an increasingly competitive electronic industry landscape.

SHSE:603416 Earnings and Revenue Growth as at Aug 2025
SHSE:603416 Earnings and Revenue Growth as at Aug 2025

Beijing Labtech Instruments (SHSE:688056)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Beijing Labtech Instruments Co., Ltd. manufactures and supplies laboratorial products and solutions to the laboratory industry worldwide, with a market capitalization of CN¥2.67 billion.

Operations: The company focuses on producing and delivering laboratory products and solutions globally.

Beijing Labtech Instruments is distinguishing itself in the high-growth tech landscape of Asia, with a notable annual revenue increase of 20.5%, outstripping the broader Chinese market's expansion rate of 12.6%. The firm's commitment to innovation is underscored by an impressive R&D expenditure, which fuels an earnings growth forecast at a vigorous rate of 28.3% per year. Recent strategic acquisitions, including a CNY 60 million investment by major financial players for a 3% stake, underscore confidence in its trajectory and potential to scale operations further within the competitive tech sector.

SHSE:688056 Earnings and Revenue Growth as at Aug 2025
SHSE:688056 Earnings and Revenue Growth as at Aug 2025

Key Takeaways

  • Click this link to deep-dive into the 174 companies within our Asian High Growth Tech and AI Stocks screener.
  • Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
  • Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Beijing Labtech Instruments might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com